---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007301"
form_type: "8-K"
ticker: "PMDI"
cik: "0000806517"
company_name: "PSYCHEMEDICS CORP"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:21:32.476029+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Psychemedics Q3 revenue down 3% to $6.5M, net loss of $0.1M; declares $0.07 dividend

## Summary
- Revenue $6.5M vs $6.7M YoY (-3%); net loss $0.1M ($0.02/sh) vs net income $0.7M ($0.13/sh).
- Nine-month revenue $19.5M (+5% YoY); net loss $0.4M ($0.07/sh) vs net income $1.0M ($0.17/sh).
- Quarterly cash dividend of $0.07/sh declared, payable Dec 16, 2022 to holders of record Dec 2, 2022.
- Prior-year quarter included $1.0M Employee Retention Credit; excluding ERC, gross margins were flat.
- Cash $3.5M at Sep 30, 2022, up from $2.0M at Dec 31, 2021; equipment financing reduced to $0.7M.

## SEC filing metadata
- accession: 0001171843-22-007301
- form_type: 8-K
- ticker: PMDI
- cik: 0000806517
- company_name: PSYCHEMEDICS CORP
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/f8k_110922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007301
- JSON: https://secwatch.observer/filing/0001171843-22-007301.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007301.txt

## Key facts
- Earnings Releases
  PSYCHEMEDICS CORP reported the third quarter ended September 30, 2022 results: revenue $6.5 million, net income $0.1 million, EPS ($0.02) per diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $6.5 million
  - Net income: $0.1 million
  - EPS: ($0.02) per diluted share
  - Result: reported results
  source text: The Company’s revenue for the quarter ended September 30, 2022, was $6.5 million versus $6.7 million for the quarter ended September 30, 2021, a decrease of 3%. Net loss for the quarter ended September 30, 2022, was $0.1 million or ($0.02) per diluted share, versus net income of $0.7 million or $0.13 per diluted share, for the comparable quarter last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm
- Earnings Releases
  PSYCHEMEDICS CORP reported the nine months ended September 30, 2022 results: revenue $19.5 million, net income $0.4 million, EPS ($0.07) per diluted share.
  - Period: the nine months ended September 30, 2022
  - Revenue: $19.5 million
  - Net income: $0.4 million
  - EPS: ($0.07) per diluted share
  - Result: reported results
  source text: The Company’s revenue for the nine months ended September 30, 2022, was $19.5 million versus $18.5 million for the comparable period in 2021, an increase of 5%. Net loss for the nine months ended September 30, 2022, was $0.4 million or ($0.07) per diluted share, versus net income of $1.0 million or $0.17 per diluted share, for the comparable period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.